Nanobiotix S.A. Stock Price

ENXTPA:NANO Community·€1.6b Market Cap

3 Narratives written by author
0 Comments on narratives written by author
10 Fair Values set on narratives written by author

Author Program NEW Create Narrative

NANO Share Price Performance

€31.14

22.93 (279.29%)

€40.00

Fair Value

€31.14

22.93 (279.29%)

22.2% undervalued

€40.00

Fair Value

€31.14

€40.00

€52.20

€60.00

Fri, 24 Jul 26

Fair Value€40.00

Share Pricen/a

NANO Community Narratives

AnalystLowTarget's

Fair Value

Fair Value €40 22.2% undervalued

Single Asset Reliance And Trial Uncertainty Will Constrain Long Term Earnings Potential

AnalystConsensusTarget's

Fair Value

Fair Value €52.2 40.3% undervalued

Radiotherapy Expansion And Nanoprimer Platform Will Shape Long Term Outlook For This Biotech

AnalystHighTarget's

Fair Value

Fair Value €60 48.1% undervalued

Radiotherapy Partnership And Curadigm Platform Will Shape A Transformative Future For Cancer Treatment

Nanobiotix

40.3% undervalued

Radiotherapy Expansion And Nanoprimer Platform Will Shape Long Term Outlook For This Biotech

AnalystConsensusTarget

Updated 7 Aug

Read Narrative

Nanobiotix

22.2% undervalued

Single Asset Reliance And Trial Uncertainty Will Constrain Long Term Earnings Potential

AnalystLowTarget

Updated 24 Jul

Read Narrative

Nanobiotix

48.1% undervalued

Radiotherapy Partnership And Curadigm Platform Will Shape A Transformative Future For Cancer Treatment

AnalystHighTarget

Updated 26 Jun

Read Narrative

Trending Discussion

No trending discussion available.

Snowflake Analysis

High growth potential and slightly overvalued.

2 Risks

2 Rewards

View Full Analysis

Nanobiotix S.A. Key Details

Last Reported Earnings

Dec 31, 2025

Next Reporting Earnings

n/a

: -0.47
: 100.00%
: -73.52%
: -109.2%

View Full Analysis

About NANO

Founded: 2003
Employees: 100
CEO: Laurent Levy
WebsiteView website: www.nanobiotix.com

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.